Description: <b>Ajoene</b> is a compound found in garlic, specifically in the oil extracted from crushed garlic cloves. It has been studied for its potential anti-cancer properties. Research suggests that ajoene may have several mechanisms by which it can inhibit the growth of cancer cells and induce apoptosis (cell death).<br>
<p><b>Ajoene</b> — an organosulfur secondary metabolite formed from garlic (Allium sativum) after crushing/processing (an allicin-derived transformation product; typically present as E/Z isomers). It is a thiol-reactive small molecule (vinyl-disulfide sulfoxide motif) studied mainly as a cytotoxic/anti-migratory agent in cancer models and as a topical antifungal. Classification: small-molecule natural product (garlic organosulfur compound). Abbreviation(s): none universally standard; often specified as E-ajoene / Z-ajoene.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Protein cysteine modification (S-thiolation / covalent adduct formation on thiol-containing targets), with downstream disruption of signaling and cytoskeletal programs</li>
<li>Pro-oxidant stress in cancer cells (ROS/H2O2 increase, redox-thiol perturbation) that can trigger intrinsic mitochondrial apoptosis</li>
<li>Cell-cycle perturbation (commonly G2/M arrest) and microtubule/cytoskeletal interference (model-dependent; isomer-dependent)</li>
<li>Anti-migration/anti-invasion phenotypes linked to intermediate filament (vimentin) network remodeling (context-dependent)</li>
<li>Secondary: NRF2-driven antioxidant response induction in some non-malignant/epithelial contexts (dose- and context-dependent)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Systemic human PK is poorly defined; ajoene is typically discussed as an allicin-derived downstream product and allicin itself is not detected in human serum after raw garlic ingestion in classic studies. Practical translation in oncology is therefore most credible for local/topical exposure or for optimized analogues; oral dietary exposure may not reproduce common in-vitro micromolar conditions reliably.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer studies use ~low–tens of µM in vitro; whether these levels are achievable systemically from diet/supplements is uncertain. Topical delivery can reach higher local concentrations (e.g., skin lesions/fungal infections), and small human topical studies exist.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical (cell culture and animal models). Small human topical evidence exists for basal cell carcinoma tumor shrinkage and for fungal skin infections (e.g., tinea pedis; chromoblastomycosis). No robust systemic oncology RCT evidence.</p>
Approximate ajoene content values for different parts of the garlic plant:<br>
Garlic bulbs: 1-5 mg of ajoene per clove<br>
Garlic scapes (green shoots): 0.5-2 mg of ajoene per 100g<br>
Garlic chives (leaves): 0.5-2 mg of ajoene per 100g<br>
Garlic microgreens: 1-5 mg of ajoene per 100g<br>
<br>
μM concentrations of ajoene that have been reported to exhibit biological activity:<br>
Antimicrobial activity: 1-10 μM<br>
Antioxidant activity: 1-50 μM<br>
Anti-inflammatory activity: 5-20 μM<br>
Anticancer activity: 10-50 μM<br>
Cardiovascular health: 5-20 μM<br>
<br>
Approximate unverified μM concentrations of ajoene that can be achieved with different amounts of garlic or garlic chives:<br>
1 clove of garlic (3g): approximately 1-5 μM of ajoene<br>
1 tablespoon of minced garlic (15g): approximately 5-15 μM of ajoene<br>
1 cup of chopped garlic (100g): approximately 30-60 μM of ajoene<br>
1 tablespoon of chopped garlic chives (15g): approximately 0.5-2 μM of ajoene<br>
1 cup of chopped garlic chives (100g): approximately 5-10 μM of ajoene<br>
1 ounce (28g) of garlic microgreens: approximately 10-30 μM of ajoene<br>
1 cup of garlic microgreens (100g): approximately 30-60 μM of ajoene<br>
1 ounce (28g) of garlic chive microgreens: approximately 5-15 μM of ajoene<br>
1 cup of garlic chive microgreens (100g): approximately 15-30 μM of ajoene<br>
<h3>Ajoene — mechanistic axes relevant to oncology translation</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Protein thiol reactivity and covalent cysteine targeting</td>
<td>↑ thiol stress; ↑ protein adducts (model-dependent)</td>
<td>↔ to ↑ adaptive antioxidant response (context-dependent)</td>
<td>P/R</td>
<td>Upstream “initiator” chemistry that can rewire multiple pathways</td>
<td>Consistent with ajoene acting as a thiol-reactive electrophile; downstream effects vary by target set and exposure.</td>
</tr>
<tr>
<td>2</td>
<td>ROS and peroxide signaling</td>
<td>↑ ROS/H2O2 (dose-dependent); ↑ oxidative damage (high concentration only)</td>
<td>↔ or ↑ cytoprotective programs (dose-dependent)</td>
<td>P</td>
<td>Oxidative stress–linked cytotoxicity in susceptible cancer models</td>
<td>Classic leukemia data show apoptosis accompanied by ROS and NF-κB activation; magnitude and direction can be model- and dose-dependent.</td>
</tr>
<tr>
<td>3</td>
<td>Mitochondria and intrinsic apoptosis</td>
<td>↑ mitochondrial apoptosis; ↑ caspase cascade (model-dependent)</td>
<td>↔ (selectivity reported in some systems)</td>
<td>R/G</td>
<td>Execution of cell death following redox/thiol perturbation</td>
<td>Topical basal cell carcinoma (BCC) work supports mitochondria-dependent apoptosis signaling in vivo/ex vivo.</td>
</tr>
<tr>
<td>4</td>
<td>NF-κB signaling</td>
<td>↑ NF-κB activity (model-dependent)</td>
<td>↔</td>
<td>P/R</td>
<td>Stress-response transcriptional program</td>
<td>NF-κB activation can be pro-survival or pro-death depending on context; in some ajoene models it co-occurs with apoptosis rather than preventing it.</td>
</tr>
<tr>
<td>5</td>
<td>Cell cycle control and microtubule/cytoskeleton dynamics</td>
<td>↑ G2/M arrest (model-dependent); ↓ proliferation</td>
<td>↔</td>
<td>R/G</td>
<td>Anti-proliferative cytostasis/cytotoxicity</td>
<td>Reported links include microtubule interference and mitotic blockade; may vary by isomer and cellular background.</td>
</tr>
<tr>
<td>6</td>
<td>Invasion and migration and vimentin intermediate filaments</td>
<td>↓ invasion/migration (requires vimentin); ↑ vimentin remodeling (context-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Anti-metastatic phenotype in vitro</td>
<td>Non-cytotoxic ajoene concentrations can remodel vimentin networks and suppress invasion/migration in vimentin-positive models.</td>
</tr>
<tr>
<td>7</td>
<td>NRF2 antioxidant response (secondary)</td>
<td>↔ to ↑ NRF2 targets (context-dependent)</td>
<td>↑ NRF2-driven cytoprotection (context-dependent)</td>
<td>R/G</td>
<td>Adaptive redox buffering</td>
<td>Ajoene can activate NRF2 and induce glutathione-related enzymes in hepatic/epithelial models; this may oppose pro-oxidant cytotoxicity at lower stress levels.</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization</td>
<td>↑ apoptosis with chemotherapy (model-dependent)</td>
<td>Unknown</td>
<td>R/G</td>
<td>Potential adjunct effect</td>
<td>Reported in leukemia models (including more resistant compartments) but not established clinically for systemic cancer therapy.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td colspan="2">Systemic exposure likely limited/variable from diet; many in-vitro studies use µM levels; isomer mixture and chemical stability complicate reproducibility; best-supported human data are topical (skin/fungal indications). Safety constraint: antiplatelet activity raises bleeding-risk concerns with anticoagulants/antiplatelets.</td>
<td>—</td>
<td>Feasibility boundary</td>
<td>Translation most plausible for topical/local delivery or for engineered analogues with validated blood stability and exposure.</td>
</tr>
</table>